Cellumed Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 12:56 pm IST
Share
Cellumed Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 48.84 million compared to KRW 95.73 million a year ago. Net loss was KRW 5,822.32 million compared to net income of KRW 654.39 million a year ago. Basic loss per share from continuing operations was KRW 135 compared to basic earnings per share from continuing operations of KRW 18 a year ago. Basic loss per share was KRW 136 compared to basic earnings per share of KRW 17 a year ago. Diluted loss per share was KRW 136 compared to diluted earnings per share of KRW 13 a year ago.
For the six months, sales was KRW 102.14 million compared to KRW 197.25 million a year ago. Net loss was KRW 11,383.62 million compared to net income of KRW 2,871.48 million a year ago. Basic loss per share from continuing operations was KRW 268 compared to basic earnings per share from continuing operations of KRW 74 a year ago. Basic loss per share was KRW 269 compared to basic earnings per share of KRW 72 a year ago. Diluted loss per share was KRW 269 compared to diluted earnings per share of KRW 67 a year ago.
CELLUMED CO., LTD., formerly Korea Bone Bank CO., LTD, is a Korea-based company engaged in the manufacture and sale of medical equipment and biosimilars. The Companyâs products consist of allografts for tissue repair; bone sponges, bone powders and demineralized bone matrixes (DBMs) for bone regeneration; biosimilars, such as bone morphogenetic protein 2 (BMP2) reagents and others, as well as medical devices, such as spinal fixation systems, joint replacements and navigation systems. The Company sells its products within domestic market and to overseas markets.
CELLUMED CO.,LTD. 
